EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacology of Heparin and Related Drugs: An Update

John Hogwood, Barbara Mulloy, Rebeca Lever, Elaine Gray, Clive P Page

Pharmacological Reviews · 2023-03 · 75 (2) · 328-379

DOI: 10.1124/pharmrev.122.000684 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2023-03. Verfasst von John Hogwood und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United Kingdom (B.M., E.G., C.P.P.);…. Hauptthemen laut MEDLINE: COVID-19, Heparin. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 739 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100 years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence, which potentiates the inhibitory action of antithrombin, a major inhibitor of the coagulation cascade. More recently it has been elucidated that heparin exhibits anti-inflammatory effect via interference of the formation of neutrophil extracellular traps and this may also contribute to heparin's antithrombotic activity. This illustrates that heparin interacts with a broad range of biomolecules, exerting both anticoagulant and nonanticoagulant actions. Since our previous review, there has been an increased interest in these nonanticoagulant effects of heparin, with the beneficial role in patients infected with SARS2-coronavirus a highly topical example. This article provides an update on our previous review with more recent developments and observations made for these novel uses of heparin and an overview of the development status of heparin-based drugs. SIGNIFICANCE STATEMENT: This state-of-the-art review covers recent developments in the use of heparin and heparin-like materials as anticoagulant, now including immunothrombosis observations, and as nonanticoagulant including a role in the treatment of SARS-coronavirus and inflammatory conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HeparinHumansAnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-Weight

Substanzen

AnticoagulantsFibrinolytic AgentsHeparinHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United Kingdom (B.M., E.G., C.P.P.); National Institute for Biological Standards and Control, South Mimms,…

Zitieren

APA

Hogwood, J., Mulloy, B., Lever, R., Gray, E., & Page, C. P. (2023). Pharmacology of Heparin and Related Drugs: An Update. Pharmacological Reviews, 75(2), 328-379. https://doi.org/10.1124/pharmrev.122.000684

Vancouver

Hogwood J, Mulloy B, Lever R, Gray E, Page CP. Pharmacology of Heparin and Related Drugs: An Update. Pharmacological Reviews. 2023;75(2):328-379. doi:10.1124/pharmrev.122.000684

BibTeX
@article{Hogwood2023,
  author = {Hogwood, John and Mulloy, Barbara and Lever, Rebeca and Gray, Elaine and Page, Clive P},
  title = {Pharmacology of Heparin and Related Drugs: An Update},
  journal = {Pharmacological Reviews},
  year = {2023},
  volume = {75},
  number = {2},
  pages = {328--379},
  doi = {10.1124/pharmrev.122.000684}
}
Kostenlos starten →